Review Article

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia

Figure 2

Currently available BCR-ABL specific TKIs for CML treatment. (a) First-generation TKI. ((b), (c), and (d)) Second-generation TKIs. (e) Third-generation TKI.
(a) Imatinib
(b) Dasatinib
(c) Nilotinib
(d) Bosutinib
(e) Ponatinib